Silexion Therapeutics Corp (SLXN)
NASDAQ: SLXN · Real-Time Price · USD
1.650
-0.110 (-6.25%)
At close: Nov 17, 2026, 4:00 PM EST
1.640
-0.010 (-0.61%)
After-hours: Nov 17, 2026, 4:18 PM EST
Silexion Therapeutics Employees
As of December 31, 2025, Silexion Therapeutics had 14 total employees, including 13 full-time and 1 part-time employees. The number of employees did not change compared to the previous year. That makes Silexion Therapeutics the 39,501st largest employer in the world and 5,804th in the United States.
Employees
14
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$997,000
Market Cap
382.27K
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 14 | 0 | - | 13 | 1 |
| Dec 31, 2024 | 14 | - | - | 11 | 3 |
Related Stocks
| Company Name | Employees |
|---|---|
| Valion Bio | 52 |
| Jaguar Health | 47 |
| Scinai Immunotherapeutics | 45 |
| Virax Biolabs Group | 26 |
| GeoVax Labs | 19 |
| Biodexa Pharmaceuticals | 11 |
| Decoy Therapeutics | 11 |
| SciSparc | 3 |
SLXN News
- 4 days ago - Silexion Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 6 days ago - Silexion Therapeutics Corp trading halted, news pending - TheFly
- 8 days ago - Silexion Therapeutics announces 1-for-24 reverse share split - TheFly
- 8 days ago - Silexion Therapeutics Announces 1-for-24 Reverse Share Split - GlobeNewsWire
- 6 weeks ago - Silexion announces first patient dosed in Phase 2/3 trial of SIL204 - TheFly
- 6 weeks ago - Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer - GlobeNewsWire
- 7 weeks ago - Silexion Therapeutics Announces Exercise of Warrants - GlobeNewsWire
- 7 weeks ago - Silexion Therapeutics reports preclinical findings for SIL204 - TheFly